Skip to main content

Table 2 PSA and ALP change

From: A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

 

PSA before switch from GnRH antagonist to agonist

PSA after switch from GnRH antagonist to agonist

p value

PSA (ng/ml)

2.7 ± 8.8

2.0 ± 5.1

0.286

 

ALP before switch from GnRH antagonist to agonist

ALP after switch from GnRH antagonist to agonist

 

ALP (IU/L)

378 ± 545

387 ± 772

0.905

  1. Abbreviations PSA prostate specific antigene, ALP alkaline phosphatase, GnRH gonadotropin releasing hormone
Back to article page

Basic and Clinical Andrology

ISSN: 2051-4190